Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - AYTU BIOPHARMA, INC | v476415_8k.htm |
Exhibit 99.1
| Aytu BioScience, Inc. | ||||||
| Proforma Balance Sheet | ||||||
| June 30, 2017 | ||||||
| Unaudited | ||||||
| 6/30/2017 | Pro Forma | Pro Forma | ||||||||||
| Consolidated | Adjustments (a) | Combined (b) | ||||||||||
| Assets | ||||||||||||
| Current assets | ||||||||||||
| Cash and cash equivalents | $ | 802,328 | $ | 10,637,752 | $ | 11,440,080 | ||||||
| Restricted cash | 75,214 | 75,214 | ||||||||||
| Accounts receivable, net | 528,039 | - | 528,039 | |||||||||
| Inventory, net | 1,312,221 | - | 1,312,221 | |||||||||
| Prepaid expenses and other | 310,760 | - | 310,760 | |||||||||
| Total current assets | 3,028,562 | 10,637,752 | 13,666,314 | |||||||||
| Fixed assets, net | 647,254 | - | 647,254 | |||||||||
| Developed technology, net | 1,337,333 | - | 1,337,333 | |||||||||
| Customer contracts, net | 77,667 | - | 77,667 | |||||||||
| Trade names, net | 164,037 | - | 164,037 | |||||||||
| Natesto asset | 9,231,072 | - | 9,231,072 | |||||||||
| Goodwill | 238,426 | - | 238,426 | |||||||||
| Patents, net | 271,278 | - | 271,278 | |||||||||
| Deposits | 2,888 | - | 2,888 | |||||||||
| Total long-term assets | 11,969,955 | - | 11,969,955 | |||||||||
| Total assets | $ | 14,998,517 | $ | 10,637,752 | $ | 25,636,269 | ||||||
| Liabilities and Stockholders' Equity | ||||||||||||
| Current liabilities | ||||||||||||
| Accounts payable and other | $ | 2,220,400 | $ | - | $ | 2,220,400 | ||||||
| Accrued liabilities | 782,536 | - | 782,536 | |||||||||
| Accrued compensation | 339,704 | - | 339,704 | |||||||||
| Deferred rent | 6,673 | - | 6,673 | |||||||||
| Contingent consideration | 261,155 | - | 261,155 | |||||||||
| Warrant derivative liability | - | 3,323,411 | 3,323,411 | |||||||||
| Total current liabilities | 3,610,468 | 3,323,411 | 6,933,879 | |||||||||
| Contingent consideration | 7,386,782 | - | 7,386,782 | |||||||||
| Deferred rent | 1,451 | - | 1,451 | |||||||||
| Total liabilities | 10,998,701 | 3,323,411 | 14,322,112 | |||||||||
| Commitments and contingencies | ||||||||||||
| Stockholders' equity | ||||||||||||
| Preferred Stock, par value $.0001; 50,000,000 shares authorized; none issued | - | 1 | 1 | |||||||||
| Common Stock, par value $.0001; 100,000,000 shares authorized; shares issued | ||||||||||||
| and outstanding 824,831 in 2017 and 187,098 in 2016 | 82 | 320 | 402 | |||||||||
| Additional paid-in capital | 73,069,463 | 7,314,020 | 80,383,483 | |||||||||
| Accumulated deficit | (69,069,729 | ) | - | (69,069,729 | ) | |||||||
| Total stockholders' equity | 3,999,816 | 7,314,341 | 11,314,157 | |||||||||
| - | ||||||||||||
| Total liabilities and stockholders' equity | $ | 14,998,517 | $ | 10,637,752 | $ | 25,636,269 | ||||||
| (a) | These are the adjustments to account for the $11.8M financing transaction on 8/15/17 |
| (b) | This is the proforma Balance sheet as if the $11.8M financing had happened on 6/30/17 |